What the FDA labels say about taking them together
Naproxen and pemetrexed
Naproxen's FDA label of March 12, 2026 names pemetrexed in its drug interactions (prescription label) section; the pemetrexed labels PlainMeds reads (4) do not name naproxen. The naproxen label: “Concomitant use of NAPRELAN and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.”
Check it at the source: the naproxen FDA label on DailyMed (effective March 12, 2026, Bayer HealthCare LLC.); the pemetrexed FDA label on DailyMed (effective October 8, 2025, Avyxa Pharma, LLC).
What does the naproxen label say about pemetrexed?
Naproxen label, drug interactions (prescription label)Pemetrexed Clinical Impact: Concomitant use of naproxen tablets and naproxen sodium tablets and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). Intervention: During concomitant use of naproxen tablets and naproxen sodium tablets and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. …
Naproxen label (Zameer Pharmaceuticals LLC, August 23, 2025), drug interactionsPemetrexed Clinical Impact: Concomitant use of NAPROXEN Tablets, Naproxen Delayed-Release Tablets, or NAPROXEN SODIUM and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). Intervention: During concomitant use of NAPROXEN Tablets, Naproxen Delayed-Release Tablets, or NAPROXEN SODIUM and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. …
Source: FDA drug label (Naprelan, NDA020353), Upsher-Smith Laboratories, LLC, effective January 8, 2026 (SPL set b8a51c9a-488e-4377-a041-436f6a2f8893), via openFDA
Source: FDA drug label (Naproxen, NDA018965), Acella Pharmaceuticals, LLC, effective January 5, 2026 (SPL set 7e6f03fb-4b36-4418-9684-f45637abbb78), via openFDA
Source: FDA drug label (Naproxen, NDA020067), Zameer Pharmaceuticals LLC, effective August 23, 2025 (SPL set d2e5553a-7c90-407c-9f07-3be65560c23a), via openFDA
Source: FDA drug label (Aleve Caplets), Bayer HealthCare LLC., effective March 12, 2026 (SPL set 02941928-128a-2c88-e063-6294a90ac6ba), via openFDA; the full label on DailyMed
What does the pemetrexed label say about naproxen?
Pemetrexed's label (effective October 8, 2025) and its 3 other brand-application labels do not name naproxen in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (AXTLE), Avyxa Pharma, LLC, effective October 8, 2025 (SPL set 9582c46c-d8b0-44b7-a2ee-9c86f5e9b7b1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Naproxen | Pemetrexed | |
|---|---|---|
| Labeled for | Fever, Rheumatoid arthritis, Osteoarthritis, Gout, Pain, Cough and cold | Lung cancer |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0565 per tablet 500 mg tablet | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once